ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 0775 • ACR Convergence 2024

    A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings

    John Stone1, Emma Culver2, Arezou Khosroshahi3, Wen Zhang4, Emanuel Della Torre5, Kazuichi Okazaki6, Yoshiya Tanaka7, Matthias Löhr8, Nicolas Schleinitz9, Lingli Dong10, Hisanori Umehara11, Marco Lanzillotta12, Zachary Wallace13, Mikael Ebbo14, George Webster15, Ferran Martinez Valle16, Manu Nayar17, Vinciane Rebours18, Cory Perugino19, Xinxin Dong20, Yanping Wu20, Nishi Rampal20 and Daniel Cimbora20, 1Massachusetts General Hospital , Harvard Medical School, Concord, MA, 2John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 3Emory University, Atlanta, GA, 4Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), 5Ospedale San Raffaele, Milan, Italy, 6University of Occupational and Environmental Health, Osaka, Japan, 7Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 8Karolinska Institutet, Stockholm, Sweden, 9Aix Marseille university, AP-HM, Marseille, France, 10Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), 11Department of Rheumatology and Immunology, Nagahama City Hospital,, Nagahama, Shiga 526-0043, Japan, Japan, 12IRCCS Ospedale San Raffaele, Milano, Italy, 13Massachusetts General Hospital, Newton, MA, 14Aix-Marseille Université, Marseille, France, 15University College Hospital London, London, United Kingdom, 16Vall d’Hebron Hospital, Barcelona, Spain, 17Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 18Beaujon Hospital, Université Paris-Cité, France, 19Massachusetts General Hospital, Boston, MA, 20Amgen Inc., Thousand Oaks, CA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
  • Abstract Number: 1211 • ACR Convergence 2024

    An Evaluation of the Efficacy, Pharmacokinetics and Safety, of the Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist RTX-GRT7039 – a Placebo-controlled Study in Patients with Osteoarthritis Knee Pain

    Thor Ostenfeld1, Stefan Ivanicius1, Roman Stancik2 and Philip G Conaghan3, 1Grunenthal GmbH, Aachen, Germany, 2National Institute of Rheumatic Diseases, Piestany, Slovenia, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: The transient receptor potential vanilloid 1 (TRPV1) is a critical driver of osteoarthritis (OA) pain. RTX-GRT7039 is an investigational medicinal product containing the active…
  • Abstract Number: 1468 • ACR Convergence 2024

    Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials

    Diego Benavent1, Victoria Navarro Compán2, Dafne Capelusnik3 and Sofia Ramiro4, 1Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 2La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 3Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 4Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: The ASAS consensus definition of ‘early axial spondyloarthritis (axSpA)’ (axial symptoms ≤ 2 years) was expert-based given the scarcity of evidence1. We conducted a…
  • Abstract Number: 1731 • ACR Convergence 2024

    Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial

    hector Chinoy1, Ashma Krishan1, Yvonne Sylvestre1, James Lilleker2, Patrick Gordon3, Sarah Tansley4, Athiveeraramapandian Prabu5, Aamir Aslam6, Andrew Snedden7 and Janine Lamb8, 1The University of Manchester, Manchester, United Kingdom, 2Northern Care Alliance NHS Trust, Salford, United Kingdom, 3nhs, London, United Kingdom, 4University of Bath, Bath, United Kingdom, 5Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, 6Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, 8University of Manchester, UK, Manchester, United Kingdom

    Background/Purpose: The aim of the study was to assess the effects of baricitinib, a JAK1/2 inhibitor, following 24 weeks of active treatment on disease activity…
  • Abstract Number: 2020 • ACR Convergence 2024

    Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase

    Peter Lipsky1 and anthony yeo2, 1AMPEL BioSolutions, Charlottesville, VA, 2Independent consultant, Ann arbor, MI

    Background/Purpose: Pegloticase is a pegylated recombinant uricase approved for treatment of chronic uncontrolled gout. Because of the development of anti-drug antibodies (ADA), persistent urate lowering…
  • Abstract Number: 2294 • ACR Convergence 2024

    Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study

    Kathy Sivils1, Steven Leonardo2, He Li3, Keying Ma4, Matthew J. Loza5, Jonathan J. Hubbard4, Kim Campbell4 and Sheng Gao4, 1Johnson & Johnson Innovative Medicine, Edmond, OK, 2Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, 3Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, 4Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 5Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA

    Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that selectively binds to the IgG-binding site of the neonatal crystallizable fragment receptor…
  • Abstract Number: 2577 • ACR Convergence 2024

    Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study

    Joan Merrill1, Amit Saxena2, Martin Aringer3, Yoshiya Tanaka4, Xiaofeng Zeng5, Peter Wung6, Ling Cheng6, Thao Doan6, Shelly Kafka6, David DCruz7 and Kristin D'Silva6, 1Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 2NYU Grossman School of Medicine, New York, NY, 3University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany, 4Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 5Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, 6AbbVie Inc., North Chicago, IL, 7The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: ABBV-599 (a combination of a selective Bruton’s tyrosine kinase inhibitor, elsubrutinib [ELS], and a selective Janus kinase inhibitor, upadacitinib [UPA]) targets a spectrum of…
  • Abstract Number: 0468 • ACR Convergence 2024

    Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks

    David Stevens1, Lene Sundbakk2, Amirhossein Kazemi2, Marte Heiberg3, Tuulikki Sokka-Isler4, Bjorn Gudbjornsson5, Kristina Lend6, Anna Rudin7, Michael Nurmohamed8, Jon Lampa9, Merete Hetland10, Mikkel Ostergaard11, Ronald Van Vollenhoven12, Tillmann Uhlig2, Espen Haavardsholm2 and Hilde Hammer3, 1St. Olavs hospital, Trondheim, Norway, 2Diakonhjemmet Hospital, Oslo, Norway, 3Diakonhjemmet Hospital, Oslo, Oslo, Norway, 4University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, 5Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 6Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 7Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 8Amsterdam University Medical Centers, Amsterdam, Netherlands, 9Karolinska University Hospital, Hässelby, Sweden, 10Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 11Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 12Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
  • Abstract Number: 0620 • ACR Convergence 2024

    Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial

    Benjamin A. Fisher1, Hendrika Bootsma2, Vibeke Strand3, Wan-Fai Ng4, Thomas Wegman5, Brandon Becker6, Jiyoon Choi6, Antoine Sreih6, Leo Chen7, Antonia Christodoulou6 and Eric Morand8, 1University of Birmingham, Birmingham, United Kingdom, 2Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 3Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 4Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, 5Bristol Myers Squibb, Beaver Falls, PA, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Richmond, BC, Canada, 8School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
  • Abstract Number: 0790 • ACR Convergence 2024

    CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study

    Jonathan Samuels1, Katherine Tse2, Wei David2, maryfe Coronel2, Fernando Bomfim2, Renata La Rocca Vieira3, Nicole Leung4, Svetlana Krasnokutsky Samuels5, Michael Toprover6 and Michael Pillinger7, 1NYU Langone, Rye Brook, NY, 2NYU Langone Health, new york, NY, 3NYU., New York, NY, 4New York University Langone Medical Center, New York, NY, 5Summit Health, Rye Brook, NY, 6New York University Langone Health, New York, NY, 7New York University Grossman School of Medicine, New York,, NY

    Background/Purpose: Knee osteoarthritis (OA) leads to progressive disability, but approved pharmacologic treatments target analgesia without affecting disease course. Colchicine is well-tolerated and inhibits inflammation thought…
  • Abstract Number: 1221 • ACR Convergence 2024

    Efficacy of Immersive Virtual Reality-based Biofeedback on Chronic Pain and Daily Life Impact in Fibromyalgia: A Pilot Randomized Controlled Trial

    Luca Chittaro1, Simone Longhino2, Marta Serafini1, Sofia Cacioppo2 and Luca Quartuccio3, 1Human-Computer Interaction Lab, Department of Mathematics, Computer Science and Physics, University of Udine, Udine, Italy, 2Division of Rheumatology, Department of Medicine, University of Udine, UDine, Italy, 3Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy

    Background/Purpose: Fibromyalgia (FM) affects 2% of the global population, causing chronic musculoskeletal pain, fatigue, sleep and mood disorders, significantly impacting quality of life. Although many…
  • Abstract Number: 1471 • ACR Convergence 2024

    Sex-related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta-analysis

    Angel Gao1, Jordi Pardo Pardo2, Steven Dang3, Lianne S Gensler4, Philip Mease5 and Lihi Eder6, 1Queens University, Kingston, Canada, 2University of Ottawa, Ottawa, Canada, 3Women's College Hospital, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, 4Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 6University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Limited information exists on sex-related differences in axial spondyloarthritis (axSpA) randomized controlled trials (RCTs). Through a systematic literature review and meta-analysis we aimed to assess…
  • Abstract Number: 1733 • ACR Convergence 2024

    Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

    Saira Sheikh1, Tahseen Mozaffar2, Vimal Derebail1, Natalie Grover1, Jonathan Hogan3, Courtney Little3, Yvonne White3, Claire Miller3, Rebecca Estremera3, Jenell Volkov3, Daniel Nunez3, Jason Stadanlick3, Mallorie Werner3, Zachary Vorndran3, Alexandra Ellis3, Jazmean Williams3, Justin Cicarelli3, Quynh Lam3, thomas Furmanak3, Chris Schmitt3, Fatemeh Nezhad3, Dan Thompson3, Samik Basu3 and David Chang3, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of California, Irvine, Irvine, CA, 3Cabaletta Bio, Philadelphia, PA

    Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
  • Abstract Number: 2023 • ACR Convergence 2024

    A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout

    Frank Fan1, Riyong Liu1 and Yu Wang2, 1Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), 2Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)

    Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
  • Abstract Number: 2342 • ACR Convergence 2024

    Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

    Lihi Eder1, Carlo Selmi2, Philip Mease3, Alexis Ogdie4, Francois Nantel5, Frederic Lavie6, Mohamed Sharaf7, Oyediran Adelakun8, Emmanouil Rampakakis9, Laura PINA VEGAS10 and Laura Coates11, 1University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 2IRCCS Istituto Clinico Humanitas, Rozzano, Italy, 3Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Nantel MedSci Consult, Montreal, QC, Canada, 6Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 7Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, 8Janssen Research & Development, LLC, Titusville, NJ, 9McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 10Leiden University Medical Center, Leiden, Netherlands, 11University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

    Background/Purpose: PsA occurs in males and females at similar rates. Females participating in randomized controlled trials (RCTs) have shown lower treatment efficacy based on composite…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology